Literature DB >> 11226425

HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1alpha degradation.

E Berra1, D E Richard, E Gothié, J Pouysségur.   

Abstract

Hypoxia-inducible factor-1alpha (HIF-1alpha) plays a central role in oxygen homeostasis. In normoxia, HIF-1alpha is a short lived protein, whereas hypoxia rapidly increases HIF-1alpha protein levels by relaxing its ubiquitin-proteasome-dependent degradation. In this study, we show that the p42/p44 MAP kinase cascade, known to phosphorylate HIF-1alpha, does not modulate the degradation/stabilization profile of HIF-1alpha. However, we present evidence that the rate of HIF-1alpha degradation depends on the duration of hypoxic stress. We demonstrate that degradation of HIF-1alpha is suppressed by: (i) inhibiting general transcription with actinomycin D or (ii) specifically blocking HIF-1-dependent transcriptional activity. In keeping with these findings, we postulate that HIF-1alpha is targetted to the proteasome via a HIF-1alpha proteasome targetting factor (HPTF) which expression is directly under the control of HIF-1-mediated transcriptional activity. Although HPTF is not yet molecularly identified, it is clearly distinct from the von Hippel-Lindau protein (pVHL).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226425     DOI: 10.1016/s0014-5793(01)02159-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  37 in total

1.  HIF-1α SUMOylation affects the stability and transcriptional activity of HIF-1α in human lens epithelial cells.

Authors:  Xiao Han; Xin-Ling Wang; Qin Li; Xiao-Xuan Dong; Jin-Song Zhang; Qi-Chang Yan
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-16       Impact factor: 3.117

2.  Suppression of hypoxia-inducible factor 1alpha (HIF-1alpha) transcriptional activity by the HIF prolyl hydroxylase EGLN1.

Authors:  Kenneth K W To; L Eric Huang
Journal:  J Biol Chem       Date:  2005-09-12       Impact factor: 5.157

Review 3.  The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling.

Authors:  Edurne Berra; Amandine Ginouvès; Jacques Pouysségur
Journal:  EMBO Rep       Date:  2006-01       Impact factor: 8.807

Review 4.  Modulation of hypoxia-inducible factors (HIF) from an integrative pharmacological perspective.

Authors:  Francisco Javier Rodríguez-Jiménez; Victoria Moreno-Manzano
Journal:  Cell Mol Life Sci       Date:  2011-10-08       Impact factor: 9.261

Review 5.  Precision medicine in pheochromocytoma and paraganglioma: current and future concepts.

Authors:  P Björklund; K Pacak; J Crona
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

6.  Gene expression profiling of the hypoxia signaling pathway in hypoxia-inducible factor 1alpha null mouse embryonic fibroblasts.

Authors:  Ajith Vengellur; Barbara G Woods; Heather E Ryan; Randall S Johnson; John J LaPres
Journal:  Gene Expr       Date:  2003

7.  Oxygen-dependent ubiquitination and degradation of hypoxia-inducible factor requires nuclear-cytoplasmic trafficking of the von Hippel-Lindau tumor suppressor protein.

Authors:  Isabelle Groulx; Stephen Lee
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

8.  Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases.

Authors:  Jan H Marxsen; Petra Stengel; Kathrin Doege; Pekka Heikkinen; Terhi Jokilehto; Thomas Wagner; Wolfgang Jelkmann; Panu Jaakkola; Eric Metzen
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

9.  HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia.

Authors:  Edurne Berra; Emmanuel Benizri; Amandine Ginouvès; Véronique Volmat; Danièle Roux; Jacques Pouysségur
Journal:  EMBO J       Date:  2003-08-15       Impact factor: 11.598

10.  Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance.

Authors:  Yanli Zhu; Lihong Zhang; Jeffrey M Gidday
Journal:  J Ocul Pharmacol Ther       Date:  2008-12       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.